VERRICA PHARMACEUTICALS INC. - COMMON STOCK

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

14 8月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

06 8月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

01 7月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

30 5月 2024 15:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

15 5月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

13 5月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

09 5月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

08 5月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

02 4月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

26 3月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

29 2月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

27 2月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

22 2月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

05 2月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

29 1月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

05 1月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

04 1月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

03 1月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

15 12月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

10 11月 2023 07:00:00 条件 Nasdaq GlobeNewswire